Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY: BMY )

54.32 -1.45 (-2.60%)
Official Closing Price Updated: 7:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2 3 4 5 6 7 8 9
...
65 66 Next >
Healthcare Stocks Are Coming On Strong In July Led By Biotech
The biotech rally gained momentum in July with rotation out of technology stocks. 
Via Talk Markets
Is Bristol-Myers Squibb's Stock Rally Justified? Bull Vs. Bear Analysts On Q2 Earnings
Bristol-Myers Squibb's stock rallies after Q2 results. Analysts have mixed views on the performance and management commentary. 
Via Benzinga
Pharma Giant's Shares Up After Impressive Q2 Earnings Release
Bristol-Myers Squibb shares were up big on the day of its earnings release. The company beat adjusted EPS estimates and saw strong growth from many drugs. 
Via MarketBeat
Wall Street's Most Accurate Analysts Say Hold These 3 Health Care Stocks With Over 3% Dividend Yields
Via Benzinga
This Bristol-Myers Squibb Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday
Via Benzinga
Bristol Myers Squibb Earnings Easily Beat On Cost Cuts; Stock Jumps
The drug giant also raised guidance. 
Via Investor's Business Daily
A Glimpse Into The Expert Outlook On Bristol-Myers Squibb Through 4 Analysts
Via Benzinga
Why I Loaded Up on This Ultra-High-Yielding ETF After the Nasdaq's Recent Slump
This ETF enables me to generate income and participate in the Nasdaq's upside potential. 
Via The Motley Fool
Topics ETFs
Dow Jumps Over 650 Points Following Inflation Data: Fear & Greed Index Moves To 'Neutral' Zone
CNN Greed & Fear Index improved to Neutral zone on Friday, with U.S. stocks closing higher and Dow Jones jumping over 650 points on inflation data. 
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
2 High-Yield Dividend Stocks That Could Shine in 2025
With interest rates expected to decline, high-yield dividend stocks offer attractive income potential and possible capital appreciation. 
Via The Motley Fool
Tech Stocks Slide On Earnings, US Economy Flexes Muscles, Small-Cap Rally Continues: This Week In The Markets
Tech earnings season disappoints investors with declines in Magnificent Seven stocks. Alphabet, Tesla miss targets, Nasdaq 100 falls 2nd week in a row. 
Via Benzinga
Topics Economy
Exposures Economy
Wall Street Enjoys Late-Week Rally On Benign Inflation Data, Dow Jones Eyes Best Session Of 2024, Tech Unwinding Stalls: What's Driving Markets Friday?
After a turbulent week in the markets, the bulls reclaimed dominance on Wall Street during Friday’s session, with indices and sectors trading in positive territory as investors welcomed the latest... 
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Why Bristol Myers Squibb Jumped Nearly 10% on Friday
The pharmaceutical company is faring far better than most investors were anticipating at this point. 
Via The Motley Fool
Why Saia Shares Are Trading Lower? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Stocks To Watch Today: 3M, BMY, And Coursera Inc.
Several major companies reported quarterly earnings this week, with 3M, Bristol-Myers Squibb, and Coursera Inc. seeing significant stock price gains. 
Via Talk Markets
Bristol Myers Squibb (BMY) Q2 2024 Earnings Call Transcript
BMY earnings call for the period ending June 30, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Crude Oil Down Over 2%; Bristol Myers Squibb Posts Upbeat Q2 Results
Via Benzinga
Exposures Fossil Fuels
BMY Stock Earnings: Bristol-Myers Squibb Beats EPS, Beats Revenue for Q2 2024
BMY stock results show that Bristol-Myers Squibb beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
Norfolk Southern Posts Upbeat Earnings, Joins Newell Brands, Charter Communications, 3M And Other Big Stocks Moving Higher On Friday
Via Benzinga
Bristol Myers Squibb Witnesses Strong Demand For 'Newer Drugs' As Q2 Earnings Beat Expectations, Raises 2024 Profit Forecast
Bristol Myers Squibb reported Q2 revenues of $12.2 billion, surpassing the consensus of $11.55B, driven by its Growth Portfolio and Eliquis. The company's adjusted EPS of $2.07 beat expectations of... 
Via Benzinga
Topics Earnings
Exposures Financial
US Stocks Look To End Week On High Note As Nvidia Leads Mega-Caps Higher In Premarket Ahead Of Key Inflation Data
After the severe pounding the tech space received in the past three sessions, it might be rebound time. However, any recovery will largely hinge on whether key inflation data confirms the continued... 
Via Benzinga
Topics Economy
Exposures Interest Rates
Bristol Myers Squibb Reports Second Quarter Financial Results for 2024
From Bristol Myers Squibb
Via Business Wire
S&P 500, Nasdaq Settle Lower As Tech Stocks Continue To Falter: Greed Index In 'Fear' Zone
Via Benzinga
Topics Stocks
Exposures US Equities
Bristol-Myers Squibb, Deckers Outdoor And 3 Stocks To Watch Heading Into Friday
Via Benzinga
DECK, SKX Higher After Earnings; PCE On Tap Friday
It’s tough to get a firm handle on this market. One day it looks like a trading rotation into undervalued equities from big run-ups elsewhere, the next day it’s a major selloff across the board. 
Via Talk Markets
2 High-Yield Dividend Stocks Billionaires Are Buying. Are They Right for You?
Billionaires are buying these stocks, but that doesn't necessarily make them right for your portfolio. 
Via The Motley Fool
Newly-Listed Psoriasis-Focused Alumis Attracts Analysts' Attention With Promising Lead Program And Modest Valuation
Guggenheim Partners initiated coverage on Alumis, highlighting its lead asset ESK-001, a TYK2 inhibitor for plaque psoriasis and systemic lupus erythematosus. With upcoming Phase 3 trials and no JAK... 
Via Benzinga
Microsoft To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Monday
Via Benzinga
AstraZeneca, Sanofi And Other Pharma Giants Pursue Chinese Deals Despite Rising US-China Strife
The aim is to strengthen their drug pipelines and expand their presence in the world's second-largest pharmaceutical market. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
65 66 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.